IL263568A - Process for the production of a dna vaccine for cancer immunotherapy - Google Patents
Process for the production of a dna vaccine for cancer immunotherapyInfo
- Publication number
- IL263568A IL263568A IL263568A IL26356818A IL263568A IL 263568 A IL263568 A IL 263568A IL 263568 A IL263568 A IL 263568A IL 26356818 A IL26356818 A IL 26356818A IL 263568 A IL263568 A IL 263568A
- Authority
- IL
- Israel
- Prior art keywords
- producing
- dna vaccine
- cancer immunotherapy
- immunotherapy
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001550 | 2016-07-13 | ||
| PCT/EP2017/067590 WO2018011289A1 (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL263568A true IL263568A (en) | 2019-01-31 |
Family
ID=56418345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL263568A IL263568A (en) | 2016-07-13 | 2018-12-06 | Process for the production of a dna vaccine for cancer immunotherapy |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10821163B2 (enExample) |
| EP (1) | EP3484503A1 (enExample) |
| JP (2) | JP7098599B2 (enExample) |
| KR (3) | KR20230079514A (enExample) |
| CN (1) | CN109475614A (enExample) |
| AU (1) | AU2017295004B2 (enExample) |
| BR (1) | BR112019000657A2 (enExample) |
| CA (1) | CA3028549A1 (enExample) |
| IL (1) | IL263568A (enExample) |
| MX (1) | MX2019000415A (enExample) |
| RU (1) | RU2019100079A (enExample) |
| SG (1) | SG11201811258UA (enExample) |
| WO (1) | WO2018011289A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190117603A (ko) | 2017-02-17 | 2019-10-16 | 백심 아게 | 신규 vegfr-2 표적화 면역요법상 접근법 |
| WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
| CA3176812A1 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| US20210213121A1 (en) * | 2018-09-05 | 2021-07-15 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| KR20220004959A (ko) | 2019-02-27 | 2022-01-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아 |
| AU2021208400A1 (en) | 2020-01-13 | 2022-08-11 | Vaximm Ag | Salmonella-based DNA vaccines in combination with an antibiotic |
| US20250340919A1 (en) * | 2022-06-30 | 2025-11-06 | Shimadzu Corporation | Method for Preparing Analysis of Microorganisms, and Method for Analyzing Microorganisms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2714071T (lt) * | 2011-05-24 | 2019-10-10 | Biontech Rna Pharmaceuticals Gmbh | Individualizuotos vakcinos nuo vėžio |
| BR112014015706A2 (pt) | 2011-12-22 | 2020-10-27 | Vaximm Ag | método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a |
| SG11201500054QA (en) * | 2012-07-05 | 2015-03-30 | Vaximm Ag | Dna vaccine for use in pancreatic cancer patients |
| DK2988762T3 (en) * | 2013-04-25 | 2018-07-16 | Vaximm Ag | SALMONELLA-BASED VECTORS FOR CANCER IMMUNITY TARGET TARGETED WILMS 'TUMORGEN WT1 |
| PL3082850T3 (pl) | 2013-12-18 | 2020-01-31 | Vaximm Gmbh | Celowana szczepionka DNA MSLN w immunoterapii nowotworu |
| JP7060324B2 (ja) * | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
-
2017
- 2017-07-12 AU AU2017295004A patent/AU2017295004B2/en active Active
- 2017-07-12 RU RU2019100079A patent/RU2019100079A/ru not_active Application Discontinuation
- 2017-07-12 WO PCT/EP2017/067590 patent/WO2018011289A1/en not_active Ceased
- 2017-07-12 CA CA3028549A patent/CA3028549A1/en active Pending
- 2017-07-12 JP JP2019501917A patent/JP7098599B2/ja active Active
- 2017-07-12 BR BR112019000657-5A patent/BR112019000657A2/pt not_active Application Discontinuation
- 2017-07-12 SG SG11201811258UA patent/SG11201811258UA/en unknown
- 2017-07-12 MX MX2019000415A patent/MX2019000415A/es unknown
- 2017-07-12 EP EP17743277.0A patent/EP3484503A1/en active Pending
- 2017-07-12 US US16/315,606 patent/US10821163B2/en active Active
- 2017-07-12 CN CN201780043297.1A patent/CN109475614A/zh active Pending
- 2017-07-12 KR KR1020237018125A patent/KR20230079514A/ko not_active Ceased
- 2017-07-12 KR KR1020197002050A patent/KR20190027834A/ko not_active Ceased
- 2017-07-12 KR KR1020267008900A patent/KR20260047288A/ko active Pending
-
2018
- 2018-12-06 IL IL263568A patent/IL263568A/en unknown
-
2020
- 2020-09-29 US US17/037,627 patent/US11590215B2/en active Active
-
2022
- 2022-04-28 JP JP2022074854A patent/JP2022097591A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019000657A2 (pt) | 2019-04-24 |
| KR20190027834A (ko) | 2019-03-15 |
| WO2018011289A1 (en) | 2018-01-18 |
| JP2019521154A (ja) | 2019-07-25 |
| JP2022097591A (ja) | 2022-06-30 |
| RU2019100079A (ru) | 2020-08-13 |
| US10821163B2 (en) | 2020-11-03 |
| KR20230079514A (ko) | 2023-06-07 |
| CN109475614A (zh) | 2019-03-15 |
| US11590215B2 (en) | 2023-02-28 |
| JP7098599B2 (ja) | 2022-07-11 |
| AU2017295004A1 (en) | 2019-01-03 |
| EP3484503A1 (en) | 2019-05-22 |
| SG11201811258UA (en) | 2019-01-30 |
| US20220072112A1 (en) | 2022-03-10 |
| US20190183996A1 (en) | 2019-06-20 |
| CA3028549A1 (en) | 2018-01-18 |
| AU2017295004B2 (en) | 2020-08-13 |
| KR20260047288A (ko) | 2026-04-07 |
| MX2019000415A (es) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264023A (en) | Nant cancer vaccine | |
| IL285722A (en) | Methods for treating alzheimer's disease | |
| EP3630130A4 (en) | PROCESS FOR GENERATING PERSONALIZED CANCER VACCINES | |
| SG11201706593SA (en) | Methods for producing virus for vaccine production | |
| EP3576751A4 (en) | RNA CANCER VACCINES | |
| EP3302794A4 (en) | epoxidation | |
| SG10201913631TA (en) | Rna for cancer therapy | |
| HUE051767T2 (hu) | Új eljárások oligonukleotidok elõállítására | |
| EP3378869A4 (en) | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDES | |
| EP3392266A4 (en) | LINACLOTIDSYNTHESEVERFAHREN | |
| GB2572275B (en) | Method for preparing Foot-and-Mouth disease vaccine | |
| MA52906A (fr) | Procédé de préparation d'amg 416 | |
| EP3439793A4 (en) | AEROSOL GENERATING DEVICE | |
| EP3398957A4 (en) | PROCESS FOR SYNTHESIS OF ETELCALCETIDE | |
| IL268677A (en) | Novel pd-l1 targeting dna vaccine for cancer immunotherapy | |
| EP3296282A4 (en) | METHOD FOR PRODUCING HYDROHALOGEN FLUOROLEFINES | |
| EP3498837A4 (en) | GENOMEDITATION PROCEDURE | |
| IL277752A (en) | Cancer vaccines | |
| EP3497088A4 (en) | epoxidation | |
| MA46454A (fr) | Procédé multi-protéase | |
| EP3441761A4 (en) | FLUORESZENZIMMUNFÄRBEVERFAHREN | |
| GB201619827D0 (en) | Process for the production of methyl methacrylate | |
| EP3558903A4 (en) | METHOD | |
| EP3484860A4 (en) | epoxidation | |
| EP3423426A4 (en) | PROCESS FOR PREPARING EXO-TETRAHYDRODICYCLOPENTADIA |